Rep. Gilbert Ray Cisneros, Jr. Purchases AtriCure, Inc. (NASDAQ:ATRC) Stock

Key Points

• Representative Gilbert Ray Cisneros, Jr. purchased between $1,001 and $15,000 in shares of AtriCure, Inc. (NASDAQ:ATRC) on May 6th, as disclosed in a recent filing.
• AtriCure has a market capitalization of $1.49 billion with its stock price fluctuating between a 12-month low of $20.20 and a high of $43.11.
• Wall Street analysts have a consensus price target of $50.67 for AtriCure, with several firms maintaining a "buy" rating despite recent target price reductions.

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of AtriCure, Inc. (NASDAQ:ATRC). In a filing disclosed on June 06th, the Representative disclosed that they had bought between $1,001 and $15,000 in AtriCure stock on May 6th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $15,001 - $50,000 in shares of SpringWorks Therapeutics NASDAQ: SWTX on 7/1/2025.
• Purchased $1,001 - $15,000 in shares of AppLovin NASDAQ: APP on 7/1/2025.
• Sold $1,001 - $15,000 in shares of Amdocs NASDAQ: DOX on 6/30/2025.
• Purchased $1,001 - $15,000 in shares of CoStar Group NASDAQ: CSGP on 6/30/2025.
• Purchased $15,001 - $50,000 in shares of CoStar Group NASDAQ: CSGP on 6/27/2025.
• Purchased $1,001 - $15,000 in shares of Xiaomi OTCMKTS: XIACF on 6/27/2025.
• Sold $1,001 - $15,000 in shares of ASML NASDAQ: ASML on 6/27/2025.
• Sold $1,001 - $15,000 in shares of Willis Towers Watson Public NASDAQ: WTW on 6/26/2025.
• Sold $1,001 - $15,000 in shares of Boston Scientific NYSE: BSX on 6/26/2025.
• Sold $1,001 - $15,000 in shares of Liberty Media Corporation - Liberty Formula One Series C NASDAQ: FWONK on 6/26/2025.

AtriCure Stock Performance

Shares of ATRC stock opened at $30.17 on Friday. The firm has a market capitalization of $1.49 billion, a price-to-earnings ratio of -37.25 and a beta of 1.56. The company has a current ratio of 4.11, a quick ratio of 2.88 and a debt-to-equity ratio of 0.16. The business's 50-day moving average price is $32.30 and its 200-day moving average price is $34.31. AtriCure, Inc. has a 12 month low of $20.20 and a 12 month high of $43.11.

AtriCure (NASDAQ:ATRC - Get Free Report) last posted its earnings results on Tuesday, April 29th. The medical device company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.11. AtriCure had a negative net margin of 7.95% and a negative return on equity of 5.68%. The business had revenue of $123.62 million for the quarter, compared to the consensus estimate of $122.92 million. During the same period last year, the company earned ($0.28) EPS. The firm's revenue was up 13.5% compared to the same quarter last year. Equities research analysts forecast that AtriCure, Inc. will post -0.6 EPS for the current year.

Institutional Trading of AtriCure

Several hedge funds have recently modified their holdings of the stock. Invesco Ltd. lifted its holdings in shares of AtriCure by 0.8% in the fourth quarter. Invesco Ltd. now owns 43,647 shares of the medical device company's stock valued at $1,334,000 after purchasing an additional 334 shares in the last quarter. Perkins Capital Management Inc. raised its position in AtriCure by 1.3% in the 4th quarter. Perkins Capital Management Inc. now owns 30,350 shares of the medical device company's stock valued at $927,000 after buying an additional 400 shares during the last quarter. Truist Financial Corp raised its position in AtriCure by 2.6% in the 4th quarter. Truist Financial Corp now owns 15,717 shares of the medical device company's stock valued at $480,000 after buying an additional 403 shares during the last quarter. State of Wyoming lifted its stake in AtriCure by 21.9% during the 4th quarter. State of Wyoming now owns 2,481 shares of the medical device company's stock valued at $76,000 after acquiring an additional 446 shares in the last quarter. Finally, LPL Financial LLC boosted its holdings in AtriCure by 5.4% during the 4th quarter. LPL Financial LLC now owns 11,465 shares of the medical device company's stock worth $350,000 after acquiring an additional 584 shares during the last quarter. Institutional investors own 99.11% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Canaccord Genuity Group cut their target price on AtriCure from $66.00 to $52.00 and set a "buy" rating on the stock in a report on Friday, March 28th. BTIG Research reaffirmed a "buy" rating on shares of AtriCure in a research note on Thursday, March 27th. Needham & Company LLC reduced their target price on AtriCure from $51.00 to $44.00 and set a "buy" rating on the stock in a report on Wednesday, April 30th. UBS Group lowered their price target on shares of AtriCure from $60.00 to $58.00 and set a "buy" rating for the company in a report on Wednesday, April 30th. Finally, Wall Street Zen lowered shares of AtriCure from a "buy" rating to a "hold" rating in a research note on Sunday, June 1st. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $50.67.

Insider Transactions at AtriCure

In other news, insider Vinayak Doraiswamy sold 2,500 shares of the stock in a transaction dated Wednesday, May 28th. The shares were sold at an average price of $33.44, for a total value of $83,600.00. Following the completion of the sale, the insider owned 73,550 shares in the company, valued at $2,459,512. This represents a 3.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 3.50% of the stock is owned by corporate insiders.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.